EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome

Registos relacionados

• Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
  Por: Su, Po-Lan, et al.
  Publicado em: (2018)
• First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
  Por: Holleman MS, et al.
  Publicado em: (2019-02-01)
• First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
  Por: Holleman, Marscha S, et al.
  Publicado em: (2019)
• First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer
  Por: Su, Po‐Lan, et al.
  Publicado em: (2020)
• Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
  Por: Xu, Jianlin, et al.
  Publicado em: (2016)